[ U.S. CDMRP – Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health | Research Funding ]


Event details

Date and time 28.05.2020  
Category Call for proposal
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Peer-Reviewed Medical Research Program (PRMRP) Awards. The PRMRP Investigator Initiated Research Award for Emerging Viral Diseases and Respiratory Health is designed to support studies that will make an important contribution toward research and/or patient care in the topic areas of Emerging Viral Diseases and/or Respiratory Health as particularly related to COVID-19. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature.

Relevance to the healthcare needs of military Service members, Veterans, military beneficiaries, and/or the American public is a key feature of this award. Applications are required to include an explanation of how the proposed project has relevance to military health.

All applications for PRMRP funding must specifically address at least one of the Topic Areas as directed by Congress; these topic areas are listed at the end of this announcement.

Funding:        max. $1’600’000

Duration:      4 years

Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. PI applicants must be independent investigators at or above the level of Assistant Professor (or equivalent).

How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.

Pre-Application Deadline: 28-May-2020, 5:00 p.m. EST
Full Application Deadline: 12-Jun-2020, 11:59 p.m. EST

Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-IIRA-COV

Further information
  • To see the program announcement, navigate to the search page on Grants.gov and search for the Opportunity Number W81XWH-20-PRMRP-IIRA-COV
  • For questions about the eBRAP or Grants.gov platforms, contact the Research Office.

FY20 Topic Areas: Emerging Viral Diseases and Respiratory Health
  • On demand identification, isolation, characterization and manufacturing of antibodies (monoclonal or polyclonal) from peripheral blood mononuclear cells (PBMCs) collected from patients with coronavirus disease 2019 (COVID-19).
  • Development of a wearable sensor that provides real-time diagnostics that can be used as a point of care for emerging viral diseases to predict illness before onset of symptoms.
  • Surveillance and predictive modeling tools that leverage artificial intelligence approaches to predict outbreaks and epidemics and support strategies for mitigating the threat of COVID-19.
  • Triage of care for COVID-19 patients requiring access to resource-intensive interventions.
  • Research to understand novel molecular and biological mechanisms of COVID-19 health impacts (e.g., microbiome) and identification/validation of biochemical, physiological, or combined biomarkers for evaluating short- and long-term health impacts from COVID-19.
  • Research to determine direct and indirect impacts of COVID-19 on military readiness and unit climate; interpersonal/family dynamics; behavioral and mental health issues such as depression, suicide, anxiety, and loneliness and other key risk factors such as substance abuse and risky health-related behaviors.
  • Research on the etiology and prevention of acute respiratory distress syndrome (ARDS) caused by host responses to coronaviruses, particularly COVID-19.
  • Development of improved methods for assessing and treating lung injury due to coronaviruses, particularly COVID-19.
  • Novel and/or innovative detection technologies or therapeutics to reduce the incidence and/or severity of ARDS and/or other lung injury secondary to coronaviruses, particularly COVID-19.
  • Development of biomarker metrics to associate the long-term health outcomes of virus-induced ARDS with degradation of physiological and physical performance.
  • Ventilation and Extracorporeal Life Support approaches and technologies to support lung function or airway management in response to COVID-19 that increase survivability and/or minimize care provider burden or exposure.
  • Pharmacological and biologic interventions for COVID-19 induced complications, including ARDS and related sequelae.

Practical information

  • General public
  • Free



research funding

Event broadcasted in